Latest Regulatory News

Hawk Resources has clinched a Mineral Exploration Agreement with Ngaanyatjarrra Traditional Owners for its Olympus Scandium Project, clearing a key hurdle ahead of planned Q2 2026 exploration. Historical data points to a significant scandium anomaly that could define a new province in Western Australia.

BPH Global inks binding deal with Temasek Innovation Holdings to validate its seaweed-based male vitality product through targeted biological assays, advancing regulatory and commercial ambitions.

Patagonia Lithium has cleared key environmental hurdles for its Formentera and Cilon mines in Argentina, advancing permits for a 1,000 tonne demonstration plant while drilling hits 150m depth at Well 7.

InteliCare has secured A$2.05 million through a placement to back its commercial expansion following major aged care contracts and initial retirement village deployments.

Manhattan Gold Corporation has secured approval to expand its Hook Lake Project footprint by 15km² on Inuit owned lands, boosting its mineral rights to 338km² with a 20-year tenure. Exploration activities including drilling and airborne surveys are set to accelerate.

Accordant Group has confirmed it has met the minimum NZD 5 million target for its rights offer, with the S.A. Hull Family Trust No. 2 stepping in to cover any shortfall. The offer is set to close on 13 May 2026, with final results due two days earlier.

PYC Therapeutics has dosed the first patient in its Phase 1b trial of PYC-003, targeting Polycystic Kidney Disease, aiming to establish safety and efficacy markers ahead of registrational studies.

Superloop showcased sustained earnings improvement and strategic fibre network expansion, spotlighting its pending Lightning Broadband acquisition to boost FTTP scale.

Desert Minerals has identified a significant north-northwesterly gold soil anomaly at its Mt Monger project, setting the stage for upcoming drilling to expand its existing JORC resource.

Zip Co’s April update highlights robust US and ANZ market expansion, with total transaction volume surging and credit losses forecast below 1.75%. The company reconfirms FY26 guidance, underpinned by AI-driven underwriting and new subscription offerings.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.

Lindian Resources reports steady progress at its Kangankunde Rare Earths Project in Malawi, maintaining schedule for first production in late 2026 with key infrastructure and regulatory milestones achieved.